Tyme Technologies Stock Forecast, Price & News

Wall Street analysts have given Tyme Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tyme Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tyme Technologies saw a drop in short interest in August. As of August 13th, there was short interest totaling 3,340,000 shares, a drop of 31.7% from the July 29th total of 4,890,000 shares. Based on an average trading volume of 7,470,000 shares, the short-interest ratio is currently 0.4 days. Currently, 2.9% of the shares of the stock are sold short.
View Tyme Technologies' Short Interest.

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Tyme Technologies.

Tyme Technologies, Inc. (NASDAQ:TYME) released its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.03) EPS for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.01.
View Tyme Technologies' earnings history.

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TYME shares have decreased by 1.0% and is now trading at $1.04.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Tyme Technologies include Veru (VERU), Collegium Pharmaceutical (COLL), Xenon Pharmaceuticals (XENE), Mersana Therapeutics (MRSN), Pliant Therapeutics (PLRX), Oramed Pharmaceuticals (ORMP), Emisphere Technologies (EMIS), Eagle Pharmaceuticals (EGRX), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Altimmune (ALT), Silence Therapeutics (SLN), Rhythm Pharmaceuticals (RYTM), Eliem Therapeutics (ELYM) and Endo International (ENDP).
View all of TYME's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Tyme Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.81%), Millennium Management LLC (1.23%), BlackRock Inc. (1.11%), Geode Capital Management LLC (0.48%), State Street Corp (0.23%) and Ergoteles LLC (0.18%). Company insiders that own Tyme Technologies stock include David Carberry, Diana F Cantor, Douglas A Michels, James Biehl, Michael Demurjian, Steve Hoffman and Tornout Jan M Van.
View institutional ownership trends for Tyme Technologies.

TYME stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., Charles Schwab Investment Management Inc., Susquehanna International Group LLP, and Bank of New York Mellon Corp. Company insiders that have sold Tyme Technologies company stock in the last year include Diana F Cantor, Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies or view top insider-selling stocks.

TYME stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, Qube Research & Technologies Ltd, Pathstone Family Office LLC, Pathstone Family Office LLC, Simplex Trading LLC, Boothbay Fund Management LLC, and LMR Partners LLP. Company insiders that have bought Tyme Technologies stock in the last two years include David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, Steve Hoffman, and Tornout Jan M Van.
View insider buying and selling activity for Tyme Technologies or or view top insider-buying stocks.

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TYME stock can currently be purchased for approximately $1.04.

Tyme Technologies has a market capitalization of $179.10 million.

Tyme Technologies employs 18 workers across the globe.

The official website for Tyme Technologies is www.tymeinc.com.

Tyme Technologies is headquartered at 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004.

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at (212) 461-2315 or via email at [email protected]